| Abstract: |
Chronic myelogenous leukemia (CML) accounts for 15% of adult leukemias. In 2005, an estimated 4,600 cases will be diagnosed, and 850 patients will die of the disease. The median age of disease onset is 53 years; however, CML occurs in all age groups, with an increasing proportion of younger patients in more recent series. ML progresses from a chronic phase to a rapidly fatal blastic phase, generally over 3 to 5 years. The blast phase is often preceded by a transition period, called the accelerated phase, which is marked by the acquisition of new cytogenetic abnormalities in 50% to 80% of patients. Several definitions of the accelerated phase of the disease are summarized. © Journal of the National Comprehensive Cancer Network. |
| Keywords: |
transplantation, homologous; gene translocation; genetics; hydroxyurea; clinical trial; disease course; neutropenia; review; interferon; diarrhea; dose response; drug dose reduction; drug withdrawal; side effect; antineoplastic agents; cytarabine; antineoplastic agent; clinical practice; cytology; metabolism; imatinib; edema; liver toxicity; erythropoietin; anemia; antimetabolites, antineoplastic; gastrointestinal symptom; thrombocytopenia; chromosomes, human, pair 9; recurrence; nccn clinical practice guidelines; calcium; steroid; allogenic bone marrow transplantation; practice guideline; hematopoietic stem cell transplantation; drug effect; pathology; chronic myeloid leukemia; pyrimidines; algorithms; cell transformation, neoplastic; rash; chronic disease; standard; chemistry; hybrid protein; recombinant fusion proteins; algorithm; cell transformation; disease progression; paracetamol; gene fusion; hematopoietic stem cells; remission; remission induction; recurrent disease; cancer relapse; chromosome breakage; translocation, genetic; hematopoietic stem cell; piperazines; acute lymphocytic leukemia; piperazine derivative; pyrimidine derivative; bone marrow transplantation; antineoplastic antimetabolite; onset age; growth factor; chromosome analysis; karyotyping; leukocytosis; cytopenia; drug interactions; diuretic agent; cytogenetic analysis; allotransplantation; thrombocytosis; bone marrow examination; fibrinolytic agent; fluid retention; chronic myelogenous leukemia; muscle cramp; blast cell crisis; drug interaction; chromosome 22; chromosome 9; chromosomes, human, pair 22; imatinib mesylate; allogeneic transplantation; apheresis; practice guidelines; hematopoietic stem cell transplant; anagrelide; leukemia, myeloid, chronic; interferons
|
